November 2024
The global biotechnology labels and packaging market size is accelerating, with forecasts predicting hundreds of millions in revenue growth between 2023 and 2034, powering sustainable infrastructure globally.
The biotechnology labels and packaging market is expected to witness considerable growth during the forecast period. Labeling and packaging is very significant factor in the biotechnology sector. End users depend on these labels to recognize as well as understand important information. The health of the consumers is greatly impacted by biotech products, thus it's necessary to give precise information on usage guidelines, date of expiration and ingredient lists. Customers can feel secure knowing that the products they get are safe for consumption and fresh due to the tamper-evident labeling and protective packaging.
The expansion of the biotechnology and pharmaceutical industries along with the rise of personalized medicine is expected to augment the growth of the biotechnology labels and packaging market during the forecast period. Furthermore, the increasing regulatory pressure from the bodies like the FDA and EMA is pushing companies to invest in high-quality labeling to maintain the compliance and prevent counterfeiting which is also anticipated to augment the growth of the market. Additionally, the rapid growth in the production of vaccines, diagnostics and biologics along with the growing need for sterile, temperature-controlled and moisture-resistant packaging are also projected to contribute to the growth of the market in the years to come.
The rising biotechnology sector is expected to fuel the growth of the biotechnology labels and packaging market within the estimated timeframe. It is expected that biotechnology will find many applications over the next two decades. Through the development of the personalized medications, personalized treatment plans, precise diagnostics as well as preventive healthcare, biotechnology has completely altered the medicine. This biotechnology revolution in medicine has been sparked by important discoveries such as genetic engineering, monoclonal antibodies, recombinant DNA technology, polymerase chain reaction, DNA sequencing and stem cell therapies. Biotechnology has impacted every aspect of medicine, from gene therapy to pharmacogenomics, biopharmaceuticals and prenatal testing, improving patient quality of life, treatment outcomes, and disease management all while reducing the healthcare costs.
Along with healthcare, biotechnology provides huge potential for the agriculture sector as well. Biotechnology gives farmers technologies that can help them produce more cheaply and efficiently. For instance, certain biotechnology crops can be modified to withstand particular herbicides, simplifying and improving weed control. Apart from crops that have been genetically modified, biotechnology has contributed to various advancements in the agriculture that do not include plants. Some examples of these developments are the use of microbial fermentation to increase the efficiency of the antibiotic manufacture and the utilization of genetic engineering to create novel animal vaccinations against diseases like rabies and disease of the foot and mouth.
Furthermore, the global expansion of the biotechnology sector is also fueled due to the increasing investments in research and development in genomics, proteomics and biomanufacturing. For instance, in December 2023, Adcentrx Therapeutics declared that its Series A+ funding had been extended. The $38 million Series A+ that was concluded in April 2023 is now strengthened by the extra $13 million. With the backing of new financing, the firm is concentrating on speeding up the clinical research of ADRX-0706 as well as the development of additional pipeline items into the clinic. As the biotechnology industry continues to innovate and expand globally, particularly in areas such as personalized medicine and complex drug formulations, the demand for advanced, compliant and protective packaging options will increase, making it a significant market driver.
The cold chain management and regulatory complexities in biotechnology packaging is likely to hinder the growth of the market within the estimated timeframe. Biotechnology products such as cell or gene therapy and biologics, can have complex labeling, packaging and distribution processes. For many of these medications, preserving the integrity and effectiveness of the drug product (DP) along the supply chain demands cryogenic (-40 °C and below) and cold chain (2-8 °C) storage, creating numerous challenges. Some of the challenges faced by packaging and labeling professionals working with these products include deciding when to utilize glass or plastic containers for the primary package, retaining label integrity in cryogenic conditions, regulatory visual and labeling market requirements, substantially smaller batch sizes than DP made in tablet form as well as logistics for transportation and protection in the cold chain and cryogenic environments.
Furthermore, specific delivery methods like prefilled syringes, auto-injectors and other equipment will be needed for some of these treatments. The process becomes more complicated since the graphics and packaging for these therapies must strictly comply with the regulatory framework for combination products. Additionally, the packaging of biologics presents particular difficulties such as process inspections and refrigeration time. Biologics become more expensive when equipment breaks down or is discovered to be malfunctioning as they must be stored in refrigeration and can only be kept outside of such temperatures for a limited period of time. In this case, the majority of the time the drugs are no longer useful, and it is also more expensive to perform destructive testing on biologics. Also, highly engineered and personalized biologics for rare diseases pose another obstacle for manufacturers of packaging and this is further expected to restrict the market growth within the estimated timeframe.
Biologics are in greater demand due to their capacity to address the root causes of disease, beneficial safety data and successful clinical outcomes. Biologics have advanced rapidly due to the advancements in proteins, nucleic acids, peptides, vaccinations, and monoclonal antibodies (mAbs), particularly in recent years. Approximately 671 biologics products had FDA approvals as of April 2023. Numerous diseases such as arthritis, cancer, kidney disease, diabetes, macular degeneration and skin disorders like ulcerative colitis, Crohn's disease and psoriasis, are treated with biologics. Furthermore, there is increasing investment in the expansion of biologics manufacturing capacities which is also expected to support the market growth in future. For instance:
This increase in demand as well as the rise in biologics production and adoption, creates numerous opportunities for the packaging manufacturers to develop solutions that not only maintain the product effectiveness but also guarantees compliance with increasingly complex regulations, all while improving product safety and sustainability throughout the supply chain.
The packaging segment held considerable market share in 2023. The increasing demand for biologics, gene therapies and vaccines is expected to support the segmental growth of the market. This is owing to the rising prevalence of chronic diseases such as cancer, autoimmune disorders and diabetes along with the shift towards personalized medicine. Furthermore, the growing demand for maintaining the right temperature range during transportation and compliance to the strict guidelines such as current Good Manufacturing Practices, requiring certifications from EMA (European Medicines Agency), FDA (Food and Drug Administration) is also expected to contribute to the growth of the segment during the forecast period. Additionally, in an effort to minimize waste during the packaging process, packaging firms like Single Use Support are developing creative solutions like multi-use shells for the single-use bags which is further anticipated to fuel the segmental growth in the years to come.
The biotechnology companies segment held the largest market share in 2023. The rapid expansion of biopharmaceutical research and development and the rising incidence of various diseases like cancer, autoimmune disorders and rare genetic conditions are anticipated to accelerate the segmental growth of the market. Additionally, the growing focus on precision medicine combined with the surge in vaccine production and biologic drug development is further projected to contribute the growth of the segment in the global market. Also, the significant investments in R&D globally as well as the rising trend of collaboration between biotechnology firms and pharmaceutical companies are further likely to fuel the segment's growth in the near future.
North America held the largest market share in the world in 2023. This is due to the presence of large number of biotechnology and pharmaceutical companies such as Amgen, Gilead Sciences, Pfizer and Biogen, among others that are at the forefront of innovation in biologics. Furthermore, the rising demand for biologics and advanced therapies and a well-established healthcare infrastructure is also expected to contribute to the regional growth of the market. Additionally, the increase in funding for biotechnology research and development from the U.S. and Canadian governments to support innovation in the biopharmaceuticals and gene therapies is projected to fuel the growth of the market in the region in the years to come.
Asia Pacific is likely to grow at fastest CAGR during the forecast period. This is owing to the rapid growth of biotechnology and pharmaceutical sectors in countries like China, India and Japan. According to the data by the India Brand Equity Foundation, by 2025, the biotechnology sector in India is projected to be valued at US$ 150 billion, and by 2030, it is likely grow to reach US$ 270–300 billion. It is projected that the Indian biotechnology sector will account for 19% of the worldwide biotechnology market by 2025. Furthermore, the rising focus on improving healthcare systems and the government initiatives and investment in biotechnology are also expected to support the regional growth of the market. Additionally, the increase in healthcare expenditure as well as a large potential for clinical research applications is also anticipated to promote the growth of the market in the region in the near future.
Some of the key players in biotechnology labels and packaging market West Pharmaceutical Services, Inc., CCL Healthcare, Aphena Pharma Solutions, RLG Healthcare, SCHOTT Pharma, ATL Corp., NADCO® Tapes & Labels, Inc., Intelsius, Earthwise Packaging, BellatRx Inc., and Sharp Services, LLC., among others.
By Product Type
By Material
By End-User
By Region
November 2024
November 2024
November 2024
November 2024
Asmita Singh is a distinguished author and consultant in the packaging industry, recognized for her unwavering passion for knowledge discovery and her commitment to providing actionable insights. She holds an MBA from the University of Mumbai and a degree in Packaging Engineering from the Indian Institute of Packaging (IIP), equipping her with a solid foundation in both business and technical aspects of packaging. With extensive experience in packaging consulting, Asmita has successfully implemented advanced research methodologies across various packaging categories, including flexible packaging, rigid packaging, sustainable packaging, and smart packaging. She generates high-quality data and delivers meaningful results that drive innovation and efficiency. Her expertise spans the globe, offering valuable consulting services to businesses seeking to enhance their packaging strategies. Asmitas work is characterized by a dedication to excellence and a keen understanding of the latest trends and technologies shaping the future of packaging.